13-32380079-G-T
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_000059.4(BRCA2):c.9190G>T(p.Asp3064Tyr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000657 in 152,124 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000059.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.9190G>T | p.Asp3064Tyr | missense_variant | Exon 24 of 27 | 5 | NM_000059.4 | ENSP00000369497.3 | ||
BRCA2 | ENST00000530893.7 | c.8821G>T | p.Asp2941Tyr | missense_variant | Exon 24 of 27 | 1 | ENSP00000499438.2 | |||
BRCA2 | ENST00000614259.2 | n.*1248G>T | non_coding_transcript_exon_variant | Exon 23 of 26 | 2 | ENSP00000506251.1 | ||||
BRCA2 | ENST00000614259 | n.*1248G>T | 3_prime_UTR_variant | Exon 23 of 25 | 2 | ENSP00000506251.1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152124Hom.: 0 Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152124Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74300
ClinVar
Submissions by phenotype
not provided Uncertain:2
- -
Observed in an individual with adenocarcinoma of the cecum and appendix (Maletzki et al., 2019); In silico analysis supports that this missense variant does not alter protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); Published functional studies demonstrate no damaging effect: ability to rescue cell lethality and lack of sensitivity to DNA-damaging drugs in a mouse embryonic stem cell (mESC)-based assay (Biswas et al., 2020); Also known as 9418G>T; This variant is associated with the following publications: (PMID: 12228710, 19043619, 29884841, 32377563, 30683709, 33293522) -
Hereditary cancer-predisposing syndrome Uncertain:2
The p.D3064Y variant (also known as c.9190G>T), located in coding exon 23 of the BRCA2 gene, results from a G to T substitution at nucleotide position 9190. The aspartic acid at codon 3064 is replaced by tyrosine, an amino acid with highly dissimilar properties. Utilizing a bioinformatics method that integrates information about protein sequence, conservation, and structure in a protein likelihood ratio, this alteration was predicted to be neutral (Karchin R et al. Cancer Inform 2008; 6:203-16). This alteration has been reported in an individual with early-onset colorectal cancer (Maletzki C et al. Oncologist, 2019 07;24:877-882). This alteration demonstrated behavior similar to wildtype in a mouse embryonic stem cell survival assay (Biswas K et al. NPJ Genom Med, 2020 Dec;5:52). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
This missense variant replaces aspartic acid with tyrosine at codon 3064 of the BRCA2 protein. Computational prediction suggests that this variant may not impact protein structure and function. A complementation and drug sensitivity study in mouse ES cells has reported the mutant protein to be functional (PMID: 33293522). This variant has been reported in an individual affected with colorectal cancer (PMID: 30683709). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
not specified Uncertain:1
Variant summary: BRCA2 c.9190G>T (p.Asp3064Tyr) results in a non-conservative amino acid change located in the BRCA2, OB3 domain (IPR015188) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251296 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.9190G>T has been reported in the literature in individuals affected with Breast and Ovarian Cancer or suspected LS (Karchin_2008, Maletzki_2019). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Both laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. -
Breast-ovarian cancer, familial, susceptibility to, 2 Uncertain:1
- -
Familial cancer of breast Uncertain:1
- -
Hereditary breast ovarian cancer syndrome Uncertain:1
This sequence change replaces aspartic acid, which is acidic and polar, with tyrosine, which is neutral and polar, at codon 3064 of the BRCA2 protein (p.Asp3064Tyr). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of BRCA2-related conditions (PMID: 10923033). ClinVar contains an entry for this variant (Variation ID: 52773). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA2 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at